Urinary tract infections - Summary of diagnostic and treatment options

被引:0
作者
Bishop, M [1 ]
Lobel, B
Weidner, W
机构
[1] City Hosp Nottingham, Dept Urol, Nottingham, England
[2] CHU Rennes, Hosp Pontchaillou, Dept Urol, Serv Urol, Rennes, France
[3] Univ Giessen, Dept Urol, D-35390 Giessen, Germany
关键词
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Urinary tract infection (UTI) can take one of several forms, including asymptomatic bacteriuria, cystitis and pyelonephritis. It can lead to local complications including abscess formation and through bacteraemia to metastatic infection and sepsis syndrome. This is defined as the presence of local symptoms with systemic inflammation and is more common in the elderly and the diabetic and immunosuppressed patient. It is an important aspect of the wider problem of nosocomial infection. Complicated UTI is defined as acute or chronic infection usually involving the renal parenchyma and associated with functional or structural urinary tract abnormality. The predominant micro-organism in UTI is Escherichia coli but in hospital acquired and complicated infection the spectrum will include Pseudomonas aeruginosa, Enterococcus spp. and Staphylococcus spp. including Staphylococcus saprophyticus. Uncomplicated UTI includes cystitis and pyelonephritis. Both can recur or relapse through failure of primary therapy. This is more likely in the setting of complicated UTI. The predominant organism is again E. coli. Treatment of UTI includes trimethoprim/sulphamethoxazole (TMP/SMX), cephalosporins, aminopenicillins, nitrofurantoin and fluoroquinolones. TMP/SMX and fluoroquinolones should not be administered to pregnant women or nursing mothers. The choice of antibiotic should reflect local resistance patterns in the hospital or community. Urosepsis should be avoidable by limiting risk factors, e.g. hospitalisation, use of catheters and stents in susceptible individuals.
引用
收藏
页码:A1 / A12
页数:12
相关论文
共 50 条
[31]   Advances and Challenges in the Diagnosis and Treatment of Urinary Tract Infections: the Need for Diagnostic Stewardship [J].
Kimberly C. Claeys ;
Natalia Blanco ;
Daniel J. Morgan ;
Surbhi Leekha ;
Kaede V. Sullivan .
Current Infectious Disease Reports, 2019, 21
[32]   Cranberries for preventing urinary tract infections: Summary of a Cochrane review [J].
Bonthu, Amrita .
EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2024, 20 (06)
[33]   Summary of the UAA-AAUS guidelines for urinary tract infections [J].
Choe, Hyun-Sop ;
Lee, Seung-Ju ;
Yang, Stephen S. ;
Hamasuna, Ryoichi ;
Yamamoto, Shingo ;
Cho, Yong-Hyun ;
Matsumoto, Tetsuro .
INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (03) :175-185
[34]   Empirical treatment of urinary tract infections [J].
Leibovici, L .
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2000, 2 (10) :804-805
[35]   THIAMPHENICOL IN TREATMENT OF URINARY TRACT INFECTIONS [J].
LIMSON, BM ;
LACSON, PS .
PHILIPPINE JOURNAL OF INTERNAL MEDICINE, 1974, 12 (03) :149-152
[36]   THE TREATMENT OF INFECTIONS OF THE URINARY TRACT WITH STREPTOMYCIN [J].
GIERTZ, G .
NORDISK MEDICIN, 1951, 46 (35) :1291-1297
[37]   TREATMENT OF URINARY TRACT INFECTIONS WITH CEPHALORIDINE [J].
SENECA, H ;
PEER, P ;
WARREN, B .
JOURNAL OF UROLOGY, 1967, 97 (01) :153-&
[38]   THE TREATMENT OF URINARY-TRACT INFECTIONS [J].
HENRIQUEZLAROCHE, C ;
RODRIGUEZITURBE, B .
INVESTIGACION CLINICA, 1984, 25 (02) :103-118
[39]   Treatment and prevention of urinary tract infections [J].
Mach, Fanny ;
Marchandin, Helene ;
Bichon, Florence .
ACTUALITES PHARMACEUTIQUES, 2020, 59 (598) :48-52
[40]   Finafloxacin for the treatment of urinary tract infections [J].
Bartoletti, Riccardo ;
Cai, Tommaso ;
Perletti, Giampaolo ;
Wagenlehner, Florian M. E. ;
Johansen, Truls E. Bjerklund .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (07) :957-963